Author(s):
Chetana G. Ahire, Ganesh B. Sonawane, Vijayraj N. Sonawane, Sunil K. Mahajan, Dipak D. Sonawane, Hitesh C. Shelar, Pooja D. Pawar
Email(s):
chetanaahire4@gmail.com
DOI:
10.52711/2231-5691.2026.00065 
Address:
Chetana G. Ahire1*, Ganesh B. Sonawane1, Vijayraj N. Sonawane1, Sunil K. Mahajan3, Dipak D. Sonawane2, Hitesh C. Shelar1, Pooja D. Pawar1
1Department of Quality Assurance, Divine College of Pharmacy, Satana, Nashik – 423301, India.
2Department of Pharmaceutics, Divine College of Pharmacy, Satana, Nashik – 423301, India.
3Department of Chemistry, Divine College of Pharmacy, Satana, Nashik – 423301, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2026
ABSTRACT:
Pharmaceutical contract manufacturing, where production is outsourced to specialized firms under another company’s brand, offers cost efficiency, scalability, and access to advanced expertise. Driven by high equipment costs, complex product demands, and the need for regulatory compliance, companies increasingly partner with Contract Manufacturing Organizations CMOs and CDMOs. While outsourcing delivers strategic benefits, it presents quality assurance challenges such as compliance consistency, data integrity, and supply chain risks. To mitigate these, firms employ robust vendor qualification, clear quality agreements, advanced monitoring, and digital tools. Emerging technologies including AI, automation, and real-time analytics are reshaping manufacturing models, enabling agility, personalized production, and stronger industry collaboration. The future of pharmaceutical outsourcing lies in technology driven, risk-managed partnerships that ensure product integrity, regulatory adherence, and competitive advantage. Overall, outsourcing and contract manufacturing remain strategic imperatives for pharmaceutical firms aiming to enhance efficiency, maintain competitive advantage, and bring products to market faster in a highly regulated global landscape. The future will be shaped by digitally integrated, collaborative partnerships between sponsors and CMOs/CDMOs, where advanced technology, risk-based QA systems, and strong governance frameworks work together to ensure product safety, regulatory compliance, and patient trust.
Cite this article:
Chetana G. Ahire, Ganesh B. Sonawane, Vijayraj N. Sonawane, Sunil K. Mahajan, Dipak D. Sonawane, Hitesh C. Shelar, Pooja D. Pawar. Outsourcing and Contract Manufacturing in Pharmaceuticals: Quality Assurance Challenges and Strategic Solutions. Asian Journal of Pharmaceutical Research. 2026; 16(4):447-5. doi: 10.52711/2231-5691.2026.00065
Cite(Electronic):
Chetana G. Ahire, Ganesh B. Sonawane, Vijayraj N. Sonawane, Sunil K. Mahajan, Dipak D. Sonawane, Hitesh C. Shelar, Pooja D. Pawar. Outsourcing and Contract Manufacturing in Pharmaceuticals: Quality Assurance Challenges and Strategic Solutions. Asian Journal of Pharmaceutical Research. 2026; 16(4):447-5. doi: 10.52711/2231-5691.2026.00065 Available on: https://asianjpr.com/AbstractView.aspx?PID=2026-16-4-12
REFERENCES:
1. Chang P, Phan TTN. Optimal manufacturing outsourcing decision based on the degree of manufacturing process standardization. In: Proc IEEE IEA; 2018. p. 49–53. doi:10.1109/iea.2018.8387069
2. Pandya EJ, Shah KV. Contract manufacturing in pharmaceutical industry. Pharm Sci Monit. 2013; 4(3).
3. Lowman M, Trott P, Hoecht A, Sellam Z. Innovation risks of outsourcing in pharmaceutical new product development. Technovation. 2012; 32(2): 99–109.
4. Getz K. The expanding outside clinical services contractor marketplace. Clin Res Regul Aff. 1997; 14(3-4): 191–204.
5. Kikerkov I, Slaninka-Miceska M, Pavlovska K, Arsovska A. Strategic outsourcing in pharmaceutical industry. KNOWLEDGE Int J. 2022; 50(4): 437–442.
6. Gilbert SM, Xia Y, Yu G. Strategic outsourcing for competing OEMs that face cost reduction opportunities. IIE Trans. 2006; 38(11): 903–915. doi:10.1080/07408170600854644
7. Harrison C. Two-for-one strike at incretins. Nat Rev Drug Discov. 2014; 13: 18–19. doi:10.1038/nrd4208
8. Song N, Bance D, Platts K. Total acquisition cost of overseas outsourcing/sourcing: a framework and a case study. J Manuf Technol Manag. 2007; 18(7): 858–875. doi:10.1108/ 17410380710817291
9. Heese HS, Perdikaki O, Kemahlıoğlu-Ziya E. Outsourcing under competition and scale economies: when to choose a competitor as a supplier. Decis Sci. 2020; 52(5): 1209–1241. doi:10.1111/ deci.12449
10. Olsen K. Productivity impacts of offshoring and outsourcing. Paris: Organisation for Economic Co-operation and Development; 2006. doi:10.1787/685237388034
11. Jennings D. Strategic sourcing: benefits, problems and a contextual model. Manag Decis. 2002; 40(1): 26–34. doi:10.1108/ 00251740210413334
12. Li S, Kang M, Haney MH. The effect of supplier development on outsourcing performance: the mediating roles of opportunism and flexibility. Prod Plan Control. 2017; 28(6-8): 599–609. doi:10.1080/09537287.2017.1309711
13. Strategic outsourcing in the pharmaceutical sector. J Commer Biotechnol. 2017. doi:10.5912/jcb772
14. Lankford WM, Parsa F. Outsourcing: a primer. Manag Decis. 1999; 37(4): 310–316.
15. Embleton PR, Wright PC. A practical guide to successful outsourcing. Empowerment Organ. 1998; 6(3): 94–106.
16. Hennig M, Hundt F, Busta S, Mikus S, Sanden PH, Sorgel A, et al. Current practice and perspectives in CRO oversight based on a survey performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa). GMS Ger Med Sci. 2017; 15: 1–15. doi:10.3205/000243
17. Przekop P. 10 key ingredients for small pharma GCP quality systems. Clin Leader. 2018. Available from: https://www.clinicalleader.com
18. Johnson J, Kanagali V, Prabu D. Third party laboratory data management: perspective with respect to clinical data management. Perspect Clin Res. 2014; 5: 41. doi:10.4103/2229-3485.124573
19. Andrianov A, Wilder B, Proupin-Perez M. ICH GCP goes risk based. Appl Clin Trials. 2015.
20. Wilkinson M, Harper B, Peacock J, Morrison R, Getz K. Assessing outsourcing oversight practices and performance. Ther Innov Regul Sci. 2019; 53(1): 71–80. doi:10.1177/ 2168479018820880
21. Kaya M, Özer Ö. Quality risk in outsourcing: noncontractible product quality and private quality cost information. Nav Res Logist. 2009; 56(7): 669–685. doi:10.1002/nav.20372
22. Bhatt A. International Council for Harmonisation E6(R2) addendum: challenges of implementation. Perspect Clin Res. 2017; 8(4): 162–166. doi:10.4103/picr.picr_124_17
23. Omuso AW. The success factors and practices that mitigate quality risks in outsourcing relationships [dissertation]. Capella University; 2009.
24. Power M, Desouza KC, Bonifazi C. The ten outsourcing traps to avoid. J Bus Strategy. 2004; 25(2): 37–42. doi:10.1108/ 02756660410525399
25. Rack C. ICH Q10 knowledge management. Eur Pharm Rev. 2019; 24(4): 59–62.
26. Rana BK, Yadav D, Yadav S. Strategic association for quality excellence: coordination between GMP, GLP, GCP, metrology, QC, and QA. In: Handbook of Quality System, Accreditation and Conformity Assessment. Singapore: Springer Nature; 2024. p. 1–21.
27. Boulaksil Y, Fransoo JC. Implications of outsourcing on operations planning: findings from the pharmaceutical industry. Int J Oper Prod Manag. 2010; 30(10): 1059–1079. doi:10.1108/ 01443571011082526
28. Nygård A. Commissioning and qualification of process equipment for the manufacturing of advanced therapy medicinal products. 2024.
29. Lebanova H, Stoev S, Petrova G. Analysis of non-compliances identified in GMP inspections between 2013 and 2022. Pharmacia. 2024; 71: 1–6.
30. International Council for Harmonisation. Pharmaceutical development Q8(R2). 2009 Aug 23.
31. Papert M, Rimpler P, Pflaum A. Enhancing supply chain visibility in a pharmaceutical supply chain: solutions based on automatic identification technology. Int J Phys Distrib Logist Manag. 2016; 46(9): 859–884.
32. Sarkar S. Supply chain security act 2023: interoperable data exchange for drug traceability. Int J Sci Res Comput Sci Eng Inf Technol. 2022; 8(3): 471–477.
33. Jones G, Chirino Chace B, Wright J. Cultural diversity drives innovation: modeling in the global pharmaceutical industry. Int J Innov Sci. 2021; 13(2): 133–144.
34. Charoo NA, Khan MA, Rahman Z. Data integrity issues in pharmaceutical industry: common observations, challenges and mitigation strategies. Int J Pharm. 2023; 631: 122503.
35. Elder D, Teasdale A. ICH Q9 quality risk management. In: ICH Quality Guidelines: An Implementation Guide. 2017. p. 579–610.
36. Dimachkie Masri M, Ramirez B, Popescu C, Reggie EM. Contract research organizations: an industry analysis. Int J Pharm Healthc Mark. 2012; 6(4): 336–350.
37. Padmanabhan A, Zhang J. Cybersecurity risks and mitigation strategies in additive manufacturing. Prog Addit Manuf. 2018; 3(1-2): 87–93. doi:10.1007/s40964-017-0036-9
38. Pres S, Wende S. The European Union Trade-Secrets Directive: to-dos for companies? IEEE Consum Electron Mag. 2017; 6(2): 105–117. doi:10.1109/mce.2016.2640618
39. Dirkareshza R, Fauzan M, Anjani A. Legal protection against misuse of trade secrets: comparison study between Indonesia and France. Indones Law Reform J. 2025; 5(1): 62–76. doi:10.22219/ ilrej.v5i1.38145
40. Bintang S, Mahfud M, Fikri F, Mujibussalim M. Confidentiality clauses in investor-state contracts for the protection of trade secrets after promulgation of the Indonesian Act on Public Information Disclosure. IIUM Law J. 2021; 29(S2): 115–141. doi:10.31436/iiumlj.v29i(s2).682
41. Calkins DM. Industrial espionage and misuse of trade secrets. Res Manag. 1965; 8(4): 265. doi:10.1080/00345334.1965.11755772
42. Kim B. Employees, trade secrets and restrictive covenants in Korea. Wonkwang Univ Leg Res Inst J. 2018; 34(2): 27–49. doi:10.22397/wlri.2018.34.2.27
43. Mohapatra S, Nag D, Tej PR. Dr Reddy’s Laboratories Ltd.: creating a competitive advantage through an empowered workforce. Emerald Emerg Mark Case Stud. 2014; 4(5): 1–14. doi:10.1108/eemcs-08-2013-0170
44. Parapalli SL. 21 CFR Part 11 compliance in MES: electronic signatures and data integrity. Int J Netw Secur. 2025; 5(1): 187–201. doi:10.55640/ijns-05-01-11
45. Ullagaddi P. Digital transformation in the pharmaceutical industry: ensuring data integrity and regulatory compliance. Int J Bus Manag. 2024; 12(3). doi:10.24940/theijbm/2024/v12/i3/bm2403-013
46. Shukar S, Babar ZUD, Gillani AH, Hu S, Hayat K, Yang C, et al. Drug shortage: causes, impact, and mitigation strategies. Front Pharmacol. 2021; 12: 693426. doi:10.3389/fphar.2021.693426
47. Mohile K. Securing the healthcare ecosystem: zero trust architecture protecting patient data across multiple access points. World J Adv Eng Technol Sci. 2025;15(3):371–378. doi:10.30574/wjaets.2025.15.3.0563
48. West T, Zentner A. Threats and major data breaches: securing third-party vendors. SSRN Electron J. 2019. doi:10.2139/ssrn.3532024
49. Hyseni B, Abazi Bexheti L. Cybersecurity and efficacity of open data platforms. IETI Trans Data Anal Forecast. 2024;2(1):4–22. doi:10.3991/itdaf.v2i1.46779
50. Elder D, Teasdale A. ICH Q9 quality risk management. 2017. p. 579–610. doi:10.1002/9781118971147.ch21